Dissecting the Natural Patterns of Progression and Senescence in Pediatric Low-Grade Glioma: From Cellular Mechanisms to Clinical Implications.
David GorodezkiMartin Ulrich SchuhmannMartin EbingerCornelia BrendlePublished in: Cells (2024)
Pediatric low-grade gliomas (PLGGs) comprise a heterogeneous set of low-grade glial and glioneuronal tumors, collectively representing the most frequent CNS tumors of childhood and adolescence. Despite excellent overall survival rates, the chronic nature of the disease bears a high risk of long-term disease- and therapy-related morbidity in affected patients. Recent in-depth molecular profiling and studies of the genetic landscape of PLGGs led to the discovery of the paramount role of frequent upregulation of RAS/MAPK and mTOR signaling in tumorigenesis and progression of these tumors. Beyond, the subsequent unveiling of RAS/MAPK-driven oncogene-induced senescence in these tumors may shape the understanding of the molecular mechanisms determining the versatile progression patterns of PLGGs, potentially providing a promising target for novel therapies. Recent in vitro and in vivo studies moreover indicate a strong dependence of PLGG formation and growth on the tumor microenvironment. In this work, we provide an overview of the current understanding of the multilayered cellular mechanisms and clinical factors determining the natural progression patterns and the characteristic biological behavior of these tumors, aiming to provide a foundation for advanced stratification for the management of these tumors within a multimodal treatment approach.
Keyphrases
- low grade
- high grade
- signaling pathway
- dna damage
- endothelial cells
- cell proliferation
- end stage renal disease
- ejection fraction
- newly diagnosed
- small molecule
- depressive symptoms
- gene expression
- single cell
- poor prognosis
- spinal cord injury
- pi k akt
- chronic pain
- patient reported outcomes
- peritoneal dialysis
- high throughput
- stem cells
- long non coding rna
- pain management
- spinal cord
- blood brain barrier
- combination therapy